Laurion Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Laurion Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-438,935	Closed	-$6.21M	–	552
2024 Q1	$6.21M	Buy	+438,935	New	+$6.68M	0.05%	235
2020 Q2	–	Sell	-2,500	Closed	-$244K	–	887
2020 Q1	$244K	Buy	+2,500	New	+$291K	﹤0.01%	653
2015 Q4	–	Sell	-6,030	Closed	-$497K	–	857
2015 Q3	$497K	Sell	6,030 -31,524	-84%	-$4.03M	0.01%	444
2015 Q2	$6.1M	Buy	+37,554	New	+$12.7M	0.06%	269

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Laurion Capital Management's ADVM Position: Q2 2024 in Review

Laurion Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 438,935 shares — an estimated $6.21M sold.

Laurion Capital Management first reported a position in ADVM in Q2 2015 and held it in 4 quarters. The position peaked at $6.21M in Q1 2024. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

Laurion Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 438,935 Adverum Biotechnologies shares in Q2 2024, an estimated $6.21M.
Laurion Capital Management first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 4 quarters.
Laurion Capital Management's Adverum Biotechnologies position peaked at $6.21M in Q1 2024.
68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.